GALT — Galectin Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$4.26
+$0.09 (+2.16%)
Galectin Therapeutics Inc (GALT) is a biotechnology company listed on NASDAQ. It is led by Joel Lewis CPA, based in 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071, with about 15 employees. Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Net income was -$8.2M. GALT currently screens at market cap $142.4M.
Use this GALT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GALT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GALT SEC filings page. Lician reads the product cache first so this HTML stays unique to Galectin Therapeutics Inc even when a live quote feed is slow.
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
GALT Key Statistics
Market Cap
$142.41M
Volume
208,684
Previous Close
$3.68
Day Range
$3.58 – $3.97
EPS
-$0.76
Revenue
$0.00
Net Income
-$47.05M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
15
GALT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$47.05M | -$41.07M | -$38.78M | -$30.53M |
| EPS (Diluted) | -$0.76 | -$0.74 | -$0.65 | -$0.52 |
Total Assets
$17.50M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$15.12M
Operating Cash Flow
-$41.77M
Free Cash Flow
$0.00
Galectin Therapeutics Inc Company Information
- President, CEO & Director
- Joel Lewis CPA
- Headquarters
- 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071
- Website
- galectintherapeutics.com
- Phone
- 678 620 3186
- IPO / Founded
- 2002-09-09
- Sector
- Healthcare
- Industry
- Biotechnology